GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Virbac SA (STU:V16) » Definitions » DeferredTaxAndRevenue

Virbac (STU:V16) DeferredTaxAndRevenue : €0 Mil (As of Jun. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Virbac DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Virbac's current deferred tax and revenue for the quarter that ended in Jun. 2023 was €0 Mil.

Virbac DeferredTaxAndRevenue Historical Data

The historical data trend for Virbac's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virbac DeferredTaxAndRevenue Chart

Virbac Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Virbac Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Virbac DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Virbac's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Virbac (STU:V16) Business Description

Traded in Other Exchanges
Address
2065m LID, 1 ere avenue, Carros, FRA, 06516
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, followed by North America and Latin America.

Virbac (STU:V16) Headlines

No Headlines